Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Recruiting 3Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 4NET 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 3Pancreatic Neuroendocrine Tumors (pNET) 1HER2 Negative Breast Cancer 1

Interventions

Specimen Handling 278Magnetic Resonance Spectroscopy 233pembrolizumab 227Carboplatin 187Cisplatin 153Biopsy 148Cyclophosphamide 143Paclitaxel 133Nivolumab 122Gemcitabine 113Bevacizumab 104Radiotherapy 92Dexamethasone 86Pemetrexed 83fludarabine 77Fluorouracil 76Docetaxel 75Doxorubicin 74atezolizumab 71Radiation 71Leucovorin 70Rituximab 67Oxaliplatin 66venetoclax 61durvalumab 61Prednisone 60Vincristine 56Cetuximab 56Lenalidomide 54Etoposide 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Chemotherapy, Adjuvant × 30 days × Clear all
NCT04567420 2026-06-03

DARE

Criterium, Inc.

Phase 2 Recruiting
70 enrolled
Breast

Breast Neoplasms

NCT05879926 2026-06-03

OFSET

NRG Oncology

Phase 3 Recruiting
3,960 enrolled
Breast

Breast Neoplasms

NCT06953882 2026-05-26

SELECT

Yale University

Phase 2 Recruiting
140 enrolled
Breast

HER2 Negative Breast Cancer

NCT07591493 2026-05-15

ADJUPANET

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Not yet recruiting
300 enrolled
EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors (pNET)

NCT05296746 2026-05-14

RIBOLARIS

SOLTI Breast Cancer Research Group

Phase 2 Active not recruiting
1,100 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡